نتایج جستجو برای: b oral vaccine pcr

تعداد نتایج: 1357331  

Journal: :Pediatrics 2014
M Nazmul Huda Zachery Lewis Karen M Kalanetra Mamunur Rashid Shaikh M Ahmad Rubhana Raqib Firdausi Qadri Mark A Underwood David A Mills Charles B Stephensen

OBJECTIVE Oral vaccine efficacy is low in less-developed countries, perhaps due to intestinal dysbiosis. This study determined if stool microbiota composition predicted infant oral and parenteral vaccine responses. METHODS The stool microbiota of 48 Bangladeshi infants was characterized at 6, 11, and 15 weeks of age by amplification and sequencing of the 16S ribosomal RNA gene V4 region and b...

2014
S Lumley C Atkinson T Haque

From 2013 an annual nasal live-attenuated influenza vaccine (LAIV—Fluenz) is available for all children in the UK aged 2 and 3 years and other ‘at-risk’ children, as part of the National Health Service (NHS) childhood vaccination programme. 2 The vaccine contains reassortant influenza viruses; two influenza A viruses (H1N1 and H3N2) and one influenza B virus, and has previously been used in chi...

A. Mirjalili G. Habibi, H. Modirrousta, K. Esmaeilnia P. Shayan

The aim of this study was to identify the cell surface cluster of differentiation (CD) markers of the cell lines infected by Theileria annulata schizont. The CD molecules are very useful for the characterization of cells and different subpopulations of leukocytes. They are usually recognized by specific antibodies using flow cytometry and immunohistochemistry. In the current stud...

Journal: :Infection and immunity 1984
J D Clements S El-Morshidy

We used the Salmonella typhi galactose epimerase (galE) mutant strain Ty21a, shown to be a safe, effective, living, attenuated oral typhoid vaccine, as a recipient for a recombinant plasmid containing the gene for production of the nontoxic B subunit of the heat-labile enterotoxin of Escherichia coli. The S. typhi derivative, strain SE12, produced heat-labile enterotoxin subunit B that was stru...

2010
C. D. Licy K. Premalatha Annie Shirwaikar Arun Shirwaikar

Problem statement: Hepatitis B is a major public health problem, killing 1-2 million people annually, despite the introduction of an effective vaccine in 1982. Approximately 400 million persons worldwide have chronic hepatitis B. This is due to problems associated with vaccine delivery, stability and cost. Hence the present challenge in Vaccinology is to develop safer, cheaper and easy-todelive...

Journal: :Lancet 2000
H Yoshida H Horie K Matsuura T Miyamura

BACKGROUND A nucleotide change from U to C at position 472 in the 5' non-coding region of the type 3 poliovirus is associated with increased neurovirulence. Moreover, the proportion of type 3 polioviruses containing this mutation (472-C revertants) correlates with the neurovirulence of a particular sample. We used mutant analysis by PCR and restriction-enzyme cleavage (MAPREC) to estimate the n...

2016
Ciaran D. Scallan Jonathan D. Lindbloom Sean N. Tucker

INTRODUCTION Oral vaccines delivered as tablets offer a number of advantages over traditional parenteral-based vaccines including the ease of delivery, lack of needles, no need for trained medical personnel, and the ability to formulate into temperature-stable tablets. We have been evaluating an oral vaccine platform based on recombinant adenoviral vectors for the purpose of creating a prophyla...

Journal: :Vector borne and zoonotic diseases 2013
Maarten J Voordouw Haley Tupper Özlem Önder Godefroy Devevey Christopher J Graves Brian D Kemps Dustin Brisson

Vaccinating wildlife is becoming an increasingly popular method to reduce human disease risks from pathogens such as Borrelia burgdorferi, the causative agent of Lyme disease. To successfully limit human disease risk, vaccines targeting the wildlife reservoirs of B. burgdorferi must be easily distributable and must effectively reduce pathogen transmission from infected animals, given that many ...

Journal: :Journal of travel medicine 2000
E T Ryan S B Calderwood

Cholera causes significant morbidity and mortality worldwide. For travelers, the risk of developing cholera per month of stay in a developing country is approximately 0.001%-0.01%, and cholera may present as traveler's diarrhea. In the United States, only a poorly tolerated, marginally effective, parenterally administered, phenol-inactivated vaccine is available. Outside the United States, 2 ad...

Journal: :Journal of health, population, and nutrition 2006
David A Sack

Correspondence and reprint requests should be addressed to: Prof. David A. Sack Executive Director ICDDR,B: Centre for Health and Population Research GPO Box 128, Dhaka 1000 Bangladesh Email: [email protected] Fax: +(880-2) 882 3116 Recent analysis of results of the 1985 vaccine trial in Bangladesh showed that a killed oral cholera vaccine could provide herd protection (1), and this finding shed...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید